Clinical Trials

23 enrolled

Sarcoma

Dendritic Cell Sarcoma, Interdigitating

NCT06561360 2026-05-26

A Study of Vemurafenib and Obinutuzumab Compared to Cladribine and Rituximab in People With Hairy Cell Leukemia (HCL)

Other hematologic neoplasm

86 enrolled

Leukemia, Hairy Cell

NCT06806033 2026-05-26

A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

100 enrolled

Cytokine Release Syndrome, Lymphoma, Non-Hodgkin, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06943872 2026-05-26

A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

630 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03223610 2026-05-22

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid (ViPOR) in Relapsed/Refractory B-cell Lymphoma

155 enrolled

Phase 1 Active not recruiting

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT04277637 2026-05-22

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

437 enrolled

Mature B-Cell Malignancies

NCT04269902 2026-05-19

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

247 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05057494 2026-05-19

MAJIC

607 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06849713 2026-05-19

BOSon

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07003295 2026-05-19

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

20 enrolled

Lymphoma, Mantle-Cell

NCT05169515 2026-05-18

A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma

Phase 1 Recruiting

121 enrolled

Lymphoma, Non-Hodgkin

NCT06651970 2026-05-18

Acalabrutinib Monotherapy vs Investigator's Choice of Treatment in Patients With CL Leukaemia and Heart Failure

Phase 4 Recruiting

60 enrolled

Heart Failure, Lymphatic Diseases, Leukemia, B-Cell

NCT06867536 2026-05-15

GLOHRT-01

Lymphoma, Lymphoma, Large B-Cell, Diffuse

NCT03269669 2026-05-13

Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma

73 enrolled

Lymphoma, Follicular

NCT03701282 2026-05-13

Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia

720 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05169658 2026-05-13

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Phase 2 Completed

42 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Marginal Zone

NCT06504199 2026-05-13

ZGR

39 enrolled

Lymphoma, Mantle-Cell

NCT06649812 2026-05-13

Testing the Effectiveness of a Combination Targeted Therapy (ViPOR) for Patients With Relapsed and/or Refractory Aggressive B-cell Lymphoma

120 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT07261163 2026-05-13

Obinutuzumab, Zanubrutinib, and Lenalidomide in First-line Treatment of Mantle Cell Lymphoma

37 enrolled

Lymphoma, Mantle-Cell

NCT07299149 2026-05-13

ZGR in TN FL

34 enrolled

Lymphoma, Follicular

NCT06073821 2026-05-11

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

652 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06634589 2026-05-11

A Study to Investigate Safety and Effectiveness of BGB-16673 in Combination With Other Agents in Participants With Relapsed or Refractory B-Cell Malignancies

80 enrolled

Neoplasms, Recurrence, Lymphoma, B-Cell

NCT03462719 2026-05-08

GLOW

211 enrolled 23 charts

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03824483 2026-05-07

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

230 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03322865 2026-05-06

Obinutuzumab in Marginal Zone Lymphoma

56 enrolled

Neoplasms, Lymphoma, B-Cell, Marginal Zone

NCT05896163 2026-05-06

MAPtivate-6

Phase 1/2 Terminated

Lymphoma, Recurrence, Lymphoma, Large B-Cell, Diffuse

NCT06191744 2026-05-06

EPCORE™FL-2

1,095 enrolled

Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Neoplasms

NCT05848765 2026-05-05

REFRACT

284 enrolled

Lymphoma, Lymphoma, Follicular

NCT05533775 2026-05-04

iMATRIX GLO

65 enrolled

Recurrence

NCT06084936 2026-05-04

GLOBRYTE

182 enrolled

Lymphoma

NCT06624085 2026-05-04

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Phase 1 Recruiting

50 enrolled

Lymphoma

NCT03737981 2026-05-01

Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia

465 enrolled 11 charts

Phase 1/2 Active not recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT03075696 2026-04-30

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma

940 enrolled 1 FDA

Lymphoma, Non-Hodgkin

NCT04608318 2026-04-30

CLL17

897 enrolled

Leukemia, B-Cell

NCT05536349 2026-04-30

Time-limited Triplet Combination of Pirtobrutinib, Venetoclax, and Obinutuzumab for Patients With Treatment-naïve Chronic Lymphocytic Leukemia (CLL) or Richter Transformation (RT)

Other hematologic neoplasm

60 enrolled

Leukemia

NCT06765317 2026-04-30

A Study of Glofitamab-based Treatment in People With Diffuse Large B-cell Lymphoma

42 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04739813 2026-04-29

Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Revlimid in Combination With Polatuzumab (ViPOR-P) in Relapsed/Refractory B-cell Lymphoma

Phase 1 Recruiting

55 enrolled

Burkitt Lymphoma, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse

NCT03863184 2026-04-28

Acalabrutinib-Lenalidomide-Rituximab in Patients With Untreated MCL

37 enrolled 9 charts

Neoplasm, Residual, Lymphoma, Mantle-Cell

NCT06252675 2026-04-20

Glofitamab With Pirtobrutinib for Relapsed or Refractory Mantle Cell Lymphoma

30 enrolled

Lymphoma, Mantle-Cell

NCT03341520 2026-04-17

GAZAI

Phase 2 Completed

89 enrolled

Lymphoma, Follicular

NCT04169737 2026-04-14

Acalabrutinib and Venetoclax With or Without Early Obinutuzumab for the Treatment of High Risk, Recurrent, or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

168 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT06090539 2026-04-14

A Study to Assess BMS-986458 Alone and in Combination With Anti-lymphoma Agents in Relapsed/Refractory Non-Hodgkin Lymphomas

308 enrolled

Lymphoma, Non-Hodgkin

NCT04450173 2026-04-13

Obinutuzumab, Ibrutinib, and Venetoclax for the Treatment of Previously Untreated Stage II-IV Follicular Lymphoma

Lymphoma, Follicular

NCT04560322 2026-04-13

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Phase 1/2 Not yet recruiting

Leukemia, Lymphocytic, Chronic, B-Cell

NCT07520006 2026-04-13

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

150 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell

NCT06428019 2026-04-09

A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)

170 enrolled

Leukemia, Lymphocytic, Chronic, B-Cell

NCT05798156 2026-04-08

R-Pola-Glo

125 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

270 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06108232 2026-04-07

Phase 2 Trial of Obinutuzumab and CC-99282 for Patients With Previously Untreated High Tumor Burden Follicular Lymphoma

33 enrolled